Funding Decisions

Translation Acceleration Grants in Predictive Markers 2018

Prostate Cancer Canada is pleased to announce the successful applications from the recent Movember Translation Acceleration Grants competition.  Prostate Cancer Canada (PCC) solicited proposals from groups developing and validating methods that can help clinicians determine the most effective treatment for their patients. The end goal is the clinical validation of the approach to improve decision making in the management of prostate cancer.
Principal Investigator Institution Title Funding
Tarek Bismar University of Calgary Characterization of novel molecular signature for accurately predicting prostate cancer progression in active surveillance $959,999
Kim Chi BC Cancer Clinical Utility of cfDNA for Prognostic and Predictive Biomarkers for Advanced Prostate Cancer $1,500,000
Housheng He University Health Network Combination of subpathology and noncoding RNA: integrating outcome prediction and treatment individualization for intermediate-risk prostate cancer $1,499,250

 

Movember Translation Acceleration Grants 2018

Principal Investigator Institution Title Funded Amount
Francois Benard BC Cancer Agency – Vancouver, BC National Program on Radioligand Therapy for Prostate Cancer $4,500,000
Funded starting January 1, 2018 for 5 years                                     Total: $4,500,000
Team Members: Institutions:
Jean-Mathieu Beauregard
Co-Principal Investigator
Université Laval
Quebec, QC
Kim Chi
Co-Principal Investigator
BC Cancer Agency
Vancouver, BC
Wanrudee Isaranuwatchai
Co-Principal Investigator
St Michael’s Hospital
Toronto, ON
Stuart Peacock
Co-Principal Investigator
University of British Columbia
Vancouver, BC
Fred Saad
Co-Principal Investigator
Centre de recherche du Centre hospitalier de l'Université de Montreal
Montreal, QC
John Valliant
Co-Principal Investigator
McMaster University
Hamilton, ON
Katherine Zukotynski
Co-Principal Investigator
McMaster University
Hamilton, ON
Frederic Arsenault
Co-Investigator
Centre de recherche du Centre hospitalier de l'Université de Montreal
Montreal, QC
Glenn Bauman
Co-Investigator
London Regional Cancer Centre
London, ON
Alejandro Berlin
Co-Investigator
University Health Network
Toronto, ON
Kelvin Chan
Co-Investigator
Sunnybrook Research Institute
Toronto, ON
Neil Fleshner
Co-Investigator
University Health Network
Toronto, ON
Ur Metser
Co-Investigator
University Health Network
Toronto, ON
Frederic Pouliot
Co-Investigator
Université Laval
Quebec, QC
Dean Regier
Co-Investigator
BC Cancer Agency
Vancouver, BC
Patrick Veit-Haibach
Co-Investigator
University Health Network
Toronto, ON


Discovery Grants 2017

Movember Discovery Grants
Principal Investigator Institution Project Title Funded Amount
Alison Allan University of Western Ontario Dynamic influence of the epithelial-to-mesenchymal transition on circulating tumor cell (CTC) generation, phenotype, and disease progression in prostate cancer $199,282
Richard Austin McMaster University Disrupting the interaction of anti-GRP78 autoantibodies to tumour cell surface GRP78 as novel therapeutic approach for the treatment of prostate cancer $193,700
Lori Brotto University of British Columbia Innovations in the treatment of sexual dysfunction and couple intimacy after prostate cancer: A randomized trial of mindfulness versus cognitive behavioural therapy $187,256
Neil Fleshner University Health Network Assessing Positive Margins at Radical Prostatectomy Using Real-Time High Resolution Prostate-Specific Membrane Antigen-Based Gamma Imaging of the Prostate Bed $192,482
Stanley Liu Sunnybrook Research Institute Interrogating radioresistance in prostate cancer: leveraging combined genomic and proteomic analyses $200,000
Christopher Mueller Queen's University Markers of poor outcome in castrate resistant prostate cancer $200,000
Caroline Pukall Queen's University Healthcare experiences and health-related quality of life in LGBTQ+ individuals with localized prostate cancer: A longitudinal, mixed-methods study with a special focus on psychosexual outcomes $199,583
John Ronald Robarts Research Institute Tumour-Activatable Minicircles: Novel Transcription-Based Blood/Urine Assays for Assessing Prostate Cancer Aggressiveness $200,000
Greg Stanisz Sunnybrook Research Institute Chemical Exchange Saturation Transfer MRI as a Biomarker of Tumour Response to Radiation Treatment $199,999
Jose Teodoro McGill University The vaculoar ATPase complex as a therapeutic target in prostate cancer $200,000
Theodorus van der Kwast University Health Network Molecular-genetic characterization of a cancer field effect associated with intraductal carcinoma of the prostate $200,000
Alexander Wyatt University of British Columbia Genomic truncation of the Androgen Receptor in poor-prognosis castration-resistant prostate cancer $200,000
Funded starting July 1, 2017 for 2 years                                          Total: $2,372,302

 

PCC Discovery Grants
Principal Investigator Institution Project Title Funded Amount
Linganatha Adisesh University of New Brunswick Cadmium, Arsenic and other metal exposures as determinants of prostate cancer in the Canadian Atlantic provinces $152,020
Kerry Courneya University of Alberta Exercise during Active Surveillance for Prostate Cancer: The ERASE Trial $76,000
Tsz Kin (Bernard) Lee BC Cancer Agency - Fraser Valley The Comprehensive Prostate Cancer Assessment on Sexual Health for Men-Who-Have-Sex-with-Men (COMPASS) $44,370
Funded starting July 1, 2017 for 2 years                                            Total: $272,370

 

PCC NextGen Awards 2017

Type Principal Investigator Institution Title Award Amount
Clinical Research Fellowship to Steven Yip Kim Chi BC Cancer Agency  - Vancouver The Germline Genetics of Prostate Cancer (GENPRO): Caring for Patients with Hereditary Prostate Cancer and their Families $75,000
Philip Feldberg Graduate Studentship to Lavinia Carabet Artem Cherkasov University of British Columbia Computer-aided discovery of small molecule inhibitors targeting the MYC-MAX complex as prospective therapeutics for castration-resistant prostate cancer $75,000
Graduate Studentship to Douglas Brown John Lewis University of Alberta Suicide gene therapy to destroy prostate cancer $75,000
Post-Doctoral Research Fellowship to Fanny Gaignier Yves Fradet Université Laval Development of a new approach for prostate cancer immunotherapy $105,000
Funded starting from July 1, 2017 for 1 or 2 years                               Total: $330,00



Translation Acceleration Grants 2017
 

Movember Translation Acceleration Grants
Principal Investigator Institution Title Funded Amount
Sylvain Martel Polytechnique Montreal Translational procedures and interventional platforms for optimal delivery of therapeutics to prostate cancer based on magneto-aerotactic MC-1 agents $1,488,000
Amina Zoubeidi University of British Columbia Targeting Neuroendocrine prostate cancer $1,495,665
Funded starting April 1, 2017                                                          Total: $2,983,665

 

PCC Translation Acceleration Grant
Principal Investigator Institution Title Funded Amount
Alexandre Zlotta Sinai Health Systems Germline Mutations in the Kallikrein 6 and DNA repair genes including BRCA1/2 and Predisposition for Aggressive Prostate Cancer $1,455,778
Funded starting April 1, 2017                                                          Total: $1,455,778



PCC Request For Proposals in Prevention 2016
 

Principal Investigator Institution Title Funded Amount
Carla Prado University of Alberta Targeted RFP in Prostate Cancer Prevention Evidence-based systematic review of modifiable risk factors for prostate cancer $24,367
Funded starting July 25, 2016 for 7 months                                       Total: $24,367



Movember Discovery Grants 2016

October 31, 2016 - Prostate Cancer Canada and Movember are proud to announce the successful recipients of the 2016 Movember Discovery Grants competition. The main goal of this program is to support researchers in that key stage of obtaining early results. The program supports both junior investigators early in their career and  more established investigators to pursue new important directions. Applications are accepted from all areas of prostate cancer research. The goal is to support researchers to generate preliminary data in prostate cancer research that would provide the basis for a more substantial research grant in the future. The applications are evaluated by a rigorous peer-review process that assesses innovation, the track record of investigator and team, the feasibility of the proposed work and the potential impact on prostate cancer.

This represents an investment of $2,270,968 over 2 years starting July 1, 2016.
 
Principal Investigator Institution Title Funded Amount
Richard Baverstock University of Calgary
Calgary, AB
Measuring the relationship between overactive bladder symptoms and prostate cancer treatment: is it bi-directional? $186,904
Vincent Fradet Université Laval
Quebec, QC
Role of gut microbiota on anti-inflammatory effect of Omega-3 in prostate cancer $197,944
Roseline Godbout University of Alberta
Edmonton, AB
Role of a novel fatty acid binding protein (FABP12) in prostate cancer lipid metabolism and progression $199,820
Housheng He University Health Network
Toronto, ON
Identifying functional long noncoding RNAs in prostate cancer $198,000
Madhuri Koti Queen's University
Kingston, ON
PTEN regulated interferon pathways as novel therapeutic targets in prostate cancer $198,000
Shawn Li Western University
London, ON
Global and quantitative kinomic and phosphoproteomic analysis of advanced prostate cancer to enable effective treatment $200,000
Hongshen Ma University of British Columbia
Vancouver, BC
Investigating castrate resistant prostate cancer through transcriptome profiling of single CTCs $200,000
Septimu Salcudean University of British Columbia
Vancouver, BC
Quantitative multimodal imaging of prostate cancer $184,108
Paul Toren Université Laval
Quebec, QC
The role of serum steroids in the development of castrate resistant prostate cancer: a secondary analysis of the PR.7 trial $115,192
Yuzhuo Wang University of British Columbia
Vancouver, BC
Identification of potential therapeutic targets for AR pathway inhibitor-resistant prostate cancer $200,000
Jian Hui Wu Lady Davis Institute for Medical Research
Montreal, QC
Development of novel GATA2 inhibitors for breaking the critical AR-GATA2 feedback loop in castration-resistant prostate cancer
$191,000
Frank Wuest University of Alberta
Edmonton, AB
Silicon-fluorine-PSMA: a winning team for early prostate cancer detection $200,000


Personnel Awards in Prostate Cancer Research 2016


October 25, 2016 - Prostate Cancer Canada is proud to announce the recipients of the 2016 Personnel Awards in Prostate Cancer Research. These awards are available to outstanding doctoral students, post- doctoral fellows and clinical research fellows studying prostate cancer. They provide recognition and funding early in academic research careers with an opportunity to continue training in an outstanding research environment.
 
This represents an investment of $495,000 over 2 years starting July 1, 2016.

 

Award Awardee Institution Title Award Amount
Great Gulf Post-Doctoral Research Fellowship Jennifer Bossio University of British Columbia
Vancouver, BC
Advances in the treatment of sexual dysfunction for men following prostate cancer: Applications for mindfulness-based cognitive therapy (MBCT) $105,000
Ellis Don Post-Doctoral Research Fellowship Lindsay Hedden University of British Columbia
Vancouver, BC
Evidence-informed decision making in cancer survivorship: evaluating a comprehensive, multi-disciplinary prostate cancer supportive care program $105,000
Paul Flumian Post-Doctoral Research Fellowship Ravi Shashi Nayana Munuganti University of British Columbia
Vancouver, BC
Development of Neural Transcription Factor BRN2 Inhibitors as Potential Therapeutics for Neuroendocrine Prostate Cancer $105,000
Stewart McInnes Post-Doctoral Research Fellowship Guy Nir University of British Columbia
Vancouver, BC
Radiomic Profiling Based on Digital Pathology for Improving Patient Stratification in Prostate Cancer Management $105,000
Philip Feldberg Graduate Studentship Natalie Fox University of Toronto/ Ontario Institute for Cancer Research
Toronto, ON
Characterization and clinical consequences of genome-transcriptome associations in intermediate risk prostate cancer $75,000


 

Movember Translation Acceleration Grants 2016

October 25, 2016 - Prostate Cancer Canada is pleased to announce the successful candidates from the Translation Acceleration Grants 2016 competition.  Grants are meant to address a significant issue in the management of prostate cancer, with a high potential of preventing disease progression and/or improving quality of life in the short term. The grants should leverage existing knowledge and have the capability to accelerate impact. The emphasis of this funding opportunity is to develop an intervention that can be studied in a patient or population study within a 5-year timeframe.
This opportunity is proudly funded by the Movember Foundation and represents a total investment of $4,477,177 over three years commencing April 1, 2016. 

 

Principal Investigator Institution Title Funded Amount
Bernhard Eigl BC Cancer Agency
Vancouver, BC
The PRIME Study - PRevention and Intervention for MEtabolic syndrome $1,498,452
Martin Gleave University of British Columbia
Vancouver, BC
Computer-aided design of novel inhibitors of Hsp27 $1,480,000
Laurence Klotz Canadian Urology Research Consortium
Toronto, ON
A randomised controlled trial of magnetic resonance imaging-targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without prior biopsy $1,498,725


Special Project in Non-Metastatic Castrate Resistant Prostate Cancer 2016

April 5, 2016 – Prostate Cancer Canada is pleased to announce the successful candidate from the Special Project in Non-Metastatic Castrate Resistant Prostate Cancer (NM-CRPC) competition. This award solicits proposals from groups interested in combining various real world data sources (i.e. detailed chart review at prostate cancer centres with health administrative databases) to obtain high quality epidemiological data, outcomes and costs among the population of prostate cancer patients in at least two provinces in Canada that together represent greater than 50% of the population.
 
The key objectives of this program are:

  • to obtain prevalence, incidence and survival probability estimates of prostate cancer, stratified by age and year of diagnosis from provincial cancer registries;
  • to identify pathways leading to and factors associated with the target condition (NM-CRPC);
  • to estimate annual incidence and prevalence of NM-CRPC, stratified probability of developing NM-CRPC and transition probabilities that characterize the prognosis from NM-CRPC to metastasis and end-of-life;
  • to estimate health care resource use and costs for health states in the recurrent disease model.
This opportunity represents a total investment of $425,437 over two years commencing April 1, 2016.  
 
Principal
Investigator
Institution Title Funded Amount
Murray Krahn University Health Network
Toronto, ON
Non-metastatic castrate resistant prostate cancer: epidemiology, clinical pathways, and health care costs $425,437


Movember Rising Stars in Prostate Cancer Research 2016

December 16, 2015 – Prostate Cancer Canada is pleased to announce the successful candidates from the Rising Stars in Prostate Cancer Research competition. These awards provide salary and research support for outstanding researchers within the first 5 years of their first academic or research appointment to develop and demonstrate independence in a career in prostate cancer research.

This opportunity, proudly funded by the Movember Foundation, represents a total investment of $1,345,199. Each award is for three years, commencing January 1, 2016, to a maximum of $450,000.

Principal
Investigator
Institution Title Funded Amount
Housheng He University Health Network
Toronto, ON
Epigenetic mechanisms underlying prostate cancer development and progression $445,200
Hon Leong Lawson Health Research Institute
London, ON
Antagonizing molecular mechanisms responsible for cancer cell extravasation to combat prostate cancer metastasis $450,000
Alexander Wyatt University of British Columbia
Vancouver, BC
Detecting druggable DNA repair defects in advanced prostate cancer $449,999

Movember Team Grant 2015

June 10, 2015 - Prostate Cancer Canada and Movember are proud to announce the recipient of the 2015 Movember Team Grant. Team grant funding supports integrated, multi-disciplinary research programs involving high-quality independent investigators who share knowledge and resources while working towards a unifying overall scientific goal. The successful team must propose a well-defined program of research that encompasses several aspects of prostate cancer research that are clearly interrelated and synergistic so that efforts and outcomes have more impact than if funded as separate grants. The program must have participating principal investigators from a minimum of three institutions and provide a formal training program.  

An international panel of reviewers was assembled to adjudicate the team grants competition. The applications were submitted to a multi-stage and layered review process; narrowing the field to a short list of applicant teams invited to a reverse site visit in Toronto.

This represents a total investment of $4,995,400 over five years starting July 1, 2015.

 
Program Director and Principal Investigator Institution Title Funded Amount
John Bell Ottawa Hospital Research Institute
Ottawa, ON
Development of a targeted oncolytic virus vaccine for the treatment of metastatic prostate cancer $4,990,498
Team Members: Institutions:
Jean-Simon Diallo
Co-Principal Investigator
Ottawa Hospital Research Institute
Ottawa, ON
Sébastien Hotte
Co-Principal Investigator
McMaster University
Hamilton, ON
Brian Lichty
Co-Principal Investigator
McMaster University
Hamilton, ON
Fred Saad
Co-Principal Investigator
Centre Hospitalier de l'Université de Montréal
Montreal, QC
Eric Belanger
Co-Investigator
Ottawa Hospital
Ottawa, ON
Jonathan Bramson
Co-Investigator
McMaster University
Hamilton, ON
Rodney Breau
Co-Investigator
Ottawa Hospital Research Institute
Ottawa, ON
Dean Fergusson
Co-Investigator
Ottawa Hospital Research Institute
Ottawa, ON
Derek Jonker
Co-Investigator
University of Ottawa
Ottawa, ON
Andrea McCart
Co-Investigator
University of Toronto
Toronto, ON
David Stojdl
Co-Investigator
Children's Hospital of Eastern Ontario
Ottawa, ON
Yonghong Wan
Co-Investigator
McMaster University
Hamilton, ON

 

Movember True NTH Survivorship Research Grants 2015

March 27, 2015 - Prostate Cancer Canada (PCC) and Movember are proud to announce the results of the Movember Targeted RFA in Survivorship Research competition. Projects aim to inform the development and delivery of interventions and best practices in follow-up care for cancer patients, survivors and their families and caregivers.

Three grants have been funded starting April 1, 2015, representing a total investment of $2,065,895 over the next three to five years.
 
Principal Investigator Institution Title Funded Amount
Shabbir Alibhai University Health Network
Toronto, ON
Toward personalizing care for older men with mCRPC - Princess Margaret Cancer Centre, University Health Network and predicting treatment toxicities
(the TOPCOP study)
$413,830
Jennifer Jones University Health Network
Toronto, ON
Prostate Cancer Survivorship 360° $1,281,025
Sylvie Lambert McGill University
Montreal, QC
Reducing anxiety and enhancing quality of life among caregivers of prostate cancer survivors: Development and evaluation of a dyadic, tailored, web-based, psychosocial and physical activity self-management programme $434,040

 

Movember Clinical Trial in Prostate Cancer 2015

March 20, 2015 - Prostate Cancer Canada (PCC) and Movember are proud to announce the results of the Movember Clinical Trials in Prostate Cancer competition. Applications were accepted for investigator-initiated clinical trials studying the iatrogenic effects of prostate cancer treatment with an overall aim of mitigating effects that are unintended and unwanted.

One grant has been funded starting April 1, 2015, representing a total investment of $3,449,136 over a five-year term.

 
Principal Investigator Institution Title Funded Amount
Jehonathan Pinthus McMaster University
Hamilton, ON
Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC) $3,449,136
 
 

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More

Prostate Cancer Canada launches first national program in radioligand therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More


Click here for news archive